BRAF and melanoma: Specifically, trametinib has been approved by the US FDA for the treatment of BRAF V600E/K-mutant melanoma, having demonstrated substantial response rates of approximately 20 % [36, 38] and improved progression-free survival and overall survival compared to chemotherapy with dacarbazine or paclitaxel [36] in this patient population.